glp 1 drugs australia GLP-1 Receptor Agonist Market Size to Hit USD 2,117.46 Million by 2035 Ozempic, GLP1 drugs drive major

Description

(U.S.) GSK plc (U.K.) Lupin Limited (India) Sun Pharmaceutical Industries Ltd

doi: 10.2337/diabetes.52.2.380 63 CoskunTSloopKWLoghinCAlsina-FernandezJUrvaSBokvistKBet al

Among the two incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), the latter has been established as having therapeutic potential for reducing elevated plasma glucose (1, 2) and body weight (3), while the former has been unable to either stimulate insulin secretion (1) or lower plasma glucose effectively in type 2 diabetes (T2D) (4)

The country has a well-developed healthcare system with widespread access to advanced pharmaceuticals, including GLP-1 therapies like Semaglutide and Tirzepatide

Patients start at 2.5 mg weekly and increase in 2.5 mg increments every four weeks, eventually reaching maintenance doses of 10 mg or 15 mg depending on tolerance and response